Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 143.78 · gapped above the open, then crossed back over prior close. High/low 144.50 at 8:45 am ET, 142.57 at 9:30 am ET.
Merck & Co., Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Pharmaceutical Preparations
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of MRK revenue | Skew |
|---|---|---|---|
| DHCDiversified Healthcare Trust | 2.60% | 0.06% | 42× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Merck & Co. Inc. (2) 55,102 0.8% 5,335 2.6% 2033”
$40M relationship42× more of DHC’s book than MRK’s
basisDHC fy2025 · closed 2025-12 $1.5BMRK fy2025 · closed 2025-12 $65.0B
FILING10-K0001075415-25-000012cik 0001075415disclosed by DHC
“Under the terms of the agreement, we are responsible for conducting and funding the study, and Merck is supplying pembrolizumab for use in the trial with no cost to us.”
FILING10-K0001193125-26-118532cik 0001782223disclosed by PYXS
“Pursuant to our collaboration and license agreement with Merck, we exclusively licensed to Merck a monospecific antibody targeting ILT4 (MK-4830), which Merck advanced in a Phase 2 clinical trial.”
FILING10-K0001193125-26-108632cik 0001098972disclosed by AGEN
“Collaboration revenue included recognition of our upfront payments pursuant to an agreement and amendment with Merck Sharp & Dohme Corp, that were terminated in prior years.”
FILING10-K0001193125-26-092614cik 0001799448disclosed by ALGS
“The increase was primarily due to $34.0 million higher revenue from our licensing agreements with Merck entered into during the second and fourth quarters of 2025, and $3.3 million higher revenue from existing and legacy collaboration agreements.”
FILING10-K0001200375-26-000006cik 0001200375disclosed by CDXS
“Merck will fund one of these phase 3 studies and we will co-fund the phase 1/2 study and the other phase 3 study, as well as supply zanzalintinib and cabozantinib.”
FILING10-K0000939767-26-000021cik 0000939767disclosed by EXEL
“We recognized $10.0 million and $10.6 million of revenue under the Merck Agreement for the years ended December 31, 2025 and 2024, respectively.”
FILING10-K0001193125-26-076918cik 0001817713disclosed by JANX
“Although we acquired the exclusive rights to sabirnetug from Merck in 2011 following Merck's strategic decision to focus its AD development efforts on a different product candidate, we did not recommence meaningful operations until we completed our first institutional fundraising in 2018.”
FILING10-K0001628280-26-021413cik 0001576885disclosed by ABOS
“In December 2021, we entered into a license agreement ("Merck License Agreement") with MSD International GmbH, an affiliate of Merck & Co., Inc. ("Merck") for the development, manufacture and commercialization of ruzasvir.”
FILING10-K0001193125-26-094159cik 0001593899disclosed by AVIR
“In the second quarter of 2024, CytomX announced a clinical collaboration with Merck to supply KEYTRUDA for evaluation of its combination with CX-801 in the Phase 1 study.”
FILING10-K0001193125-26-107146cik 0001501989disclosed by CTMX
“Under the MSD Agreements, we act as the sponsor of the clinical trials at our own costs and MSD has agreed to supply to us, at its own cost, pembrolizumab for use in such trials.”
FILING10-K0001193125-26-130395cik 0001861123disclosed by EIKN
“As part of our post-spinoff plan to further optimize our manufacturing and supply network, we will continue to separate our supply chain through planned exits from supply agreements with Merck through 2031.”
FILING10-K0001628280-26-011125cik 0001821825disclosed by OGN
“Beginning in mid-2024, the Company observed a significant decline in shipments from its distributor and commercialization partner in China, Chongqing Zhifei Biological Products Co., Ltd. (Zhifei), to disease and control prevention institutions and correspondingly into the points of vaccination compared with prior quarters of 2024, resulting in above normal inventory levels at Zhifei.”
FILING10-K0000310158-26-000063cik 0000310158
“Through December 31, 2025, we have funded our operations with proceeds from our initial public offering ("IPO") in October 2020, sales of preferred stock, term loans, an upfront payment of $15.0 million we received in July 2020 under the Research Collaboration and Exclusive License Agreement (the "Merck Collaboration Agreement") with Merck Sharp & Dohme Corp. ("Merck"), proceeds we received in December 2021 under the Lilly SPA of $80.0 million; an upfront payment of $300.0 million received in January 2022 under the Lilly Collaboration Agreement; a payment of $5.0 million received from Merck under the Merck Collaboration Agreement in the third quarter of 2022 for the achievement of a research milestone; net 70 Table of Contents proceeds of $102.8 million, after deducting underwriting discounts, commissions and other offering expenses, from the May 2024 Offering; and net proceeds from our ATM Facility of $0.5 million.”
FILING10-K0001628280-26-016814cik 0001822462disclosed by FHTX
“• a $2.0 million increase in revenue recognized under our former exclusive license and collaboration agreement with Merck upon receipt of notice of termination in September 2025.”
FILING10-K0001628280-26-012000cik 0001662579disclosed by CCCC
“In June 2014, we entered into a License Agreement with Merck to develop α7 receptor PAMs targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. Under the 2014 License Agreement, Merck funded certain research and”
FILING10-K0001193125-25-223338cik 0001191070disclosed by NEUP
“our future business with the U.S. Department of Veterans Affairs' Million Veteran Program ("VA MVP"), ModernaTX, Inc. ("Moderna"), Merck & Co., Inc. ("Merck"), and other collaboration partners and customers;”
FILING10-K0001193125-26-076615cik 0001527753disclosed by PSNL
“Acquired Verona Pharma plc (Verona Pharma), a biopharmaceutical company focused on respiratory diseases, through which Merck obtained Ohtuvayre, a product approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).”
FILING10-K0000310158-26-000063cik 0000310158
“In July 2021, we entered into clinical collaboration with Merck, a leader in immuno-oncology. The clinical collaboration and supply agreement includes open-label, dose escalation and expansion clinical studies to evaluate our anti-CTLA-4 mAb product candidate, ADG126 in combination with pembrolizumab for patients with advanced/metastatic solid tumors. Under terms of the agreement, Merck provides pembrolizumab and input on our clinical trials evaluating pembrolizumab in combination with ADG126”
FILING20-F0001104659-26-038612cik 0001818838disclosed by ADAG
“Given the potential immunobiologic and pharmacodynamic synergy between GPS and an immune check-point inhibitor (e.g., PD-1 inhibitor), we entered into a Clinical Trial Collaboration and Supply Agreement with Merck (known as MSD outside the United States and Canada), to assess the efficacy and safety of GPS in combination with Merck's anti-PD-1 therapy pembrolizumab with exploratory long-term follow-up for OS and safety.”
FILING10-K0001390478-26-000003cik 0001390478disclosed by SLS
“With the exclusive global license agreement with Merck”
FILING10-K0001140361-26-012030cik 0001472091disclosed by PDSB
“In 2025, MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) licensed Evaxion's vaccine candidate EVX-B3 for a cash payment of $7.5 million, and Evaxion is eligible for future development, regulatory and sales milestone payments as well as royalties on net sales”
FILING20-F0001171843-26-001346cik 0001828253disclosed by EVAX
“In June 2024, Immutep entered into its third and most important collaboration with Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) for the registrational Phase III trial in non-small cell lung cancer called TACTI-004. In addition to working together, MSD was also supplying KEYTRUDA at no cost for the trial.”
FILING20-F0001193125-25-249346cik 0001506184disclosed by IMMP
“we entered into a supply agreement with Merck to evaluate the combination of INT230-6 with Keytruda ® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid malignancies, including pancreatic, bile duct, squamous cell and non-MSI high colon cancers.”
FILING10-K0001567264-26-000024cik 0001567264disclosed by INTS
Watchlist prices, news filtered to it, and its next report on your desk.
Merck & Co., Inc. has 19 disclosed suppliers and 14 disclosed customers. Each one is named in an SEC filing, either Merck & Co., Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
MRK (Merck & Co., Inc.) has 19 disclosed suppliers and 14 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: PDSB +55.35%, in the health bundle.